-
EP3784271
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3784271
| EP3784271 - NEOEPITOPE VACCINE AND IMMUNE STIMULANT COMBINATIONS AND METHODS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 08.08.2025 Database last updated on 07.04.2026 | |
| Former | Request for examination was made Status updated on 29.01.2021 | ||
| Former | The international publication has been made Status updated on 16.05.2020 | Most recent event Tooltip | 27.03.2026 | New entry: Renewal fee paid | Applicant(s) | For all designated states NantCell, Inc. 9920 Jefferson Boulevard Culver City, CA 90232 / US | [2021/09] | Inventor(s) | 01 /
RABIZADEH, Shahrooz 9920 Jefferson Boulevard Culver City, CA 90232 / US | 02 /
SOON-SHIONG, Patrick 9920 Jefferson Boulevard Culver City, CA 90232 / US | [2021/09] | Representative(s) | Tomkins & Co 5 Dartmouth Road Dublin 6 / IE | [2021/09] | Application number, filing date | 19882224.9 | 22.04.2019 | [2021/09] | WO2019US28550 | Priority number, date | US201862661298P | 23.04.2018 Original published format: US 201862661298 P | [2021/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2020096640 | Date: | 14.05.2020 | Language: | EN | [2020/20] | Type: | A2 Application without search report | No.: | EP3784271 | Date: | 03.03.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.05.2020 takes the place of the publication of the European patent application. | [2021/09] | Search report(s) | International search report - published on: | US | 30.07.2020 | (Supplementary) European search report - dispatched on: | EP | 15.02.2022 | Classification | IPC: | A61K38/20, A61K39/00, A61K39/395, A61P35/00, A61P37/04, C07K16/28 | [2021/09] | CPC: |
C07K16/2827 (EP,US);
C07K14/7155 (US);
A61K38/00 (US);
A61K38/208 (EP);
A61K39/3955 (EP,US);
A61K40/11 (EP,US);
A61K40/24 (US);
A61K40/30 (EP,US);
A61K40/42 (US);
A61K40/4201 (EP,US);
A61K40/4217 (EP,US);
A61K9/0019 (US);
C07K16/2818 (US);
A61K2039/5256 (US);
A61K2039/545 (EP,US);
| C-Set: |
A61K38/208, A61K2300/00 (EP);
A61K39/3955, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/09] | Title | German: | NEOEPITOP-IMPFSTOFFE SOWIE IMMUNSTIMULIERENDE KOMBINATIONEN UND VERFAHREN | [2021/09] | English: | NEOEPITOPE VACCINE AND IMMUNE STIMULANT COMBINATIONS AND METHODS | [2021/09] | French: | VACCIN À NÉO-ÉPITOPE ET COMBINAISONS ET PROCÉDÉS DE STIMULATION IMMUNITAIRE | [2021/09] | Entry into regional phase | 21.09.2020 | National basic fee paid | 21.09.2020 | Search fee paid | 21.09.2020 | Designation fee(s) paid | 21.09.2020 | Examination fee paid | Examination procedure | 21.09.2020 | Examination requested [2021/09] | 29.08.2022 | Amendment by applicant (claims and/or description) | 07.08.2025 | Despatch of a communication from the examining division (Time limit: M04) | 03.10.2025 | Reply to a communication from the examining division | 30.01.2026 | Despatch of a communication from the examining division (Time limit: M04) | 24.03.2026 | Reply to a communication from the examining division | Fees paid | Renewal fee | 29.04.2021 | Renewal fee patent year 03 | 25.03.2022 | Renewal fee patent year 04 | 23.03.2023 | Renewal fee patent year 05 | 24.04.2024 | Renewal fee patent year 06 | 24.04.2025 | Renewal fee patent year 07 | 26.03.2026 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] WO2015069770 (COGNATE BIOSERVICES INC et al.) | [A] WO2016172249 (ETUBICS CORP et al.) | [A] WO2017143449 (CHILDREN'S HOSPITAL OF EASTERN ONTARIO RES INST INC et al.) | [A] WO2016004060 (ALTOR BIOSCIENCE CORP et al.) | [A] KABACAOGLU DERYA ET AL: "Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options", FRONTIERS IN IMMUNOLOGY, vol. 9, 1 January 2018 (2018-01-01), pages 1878, XP055821506, DOI: 10.3389/fimmu.2018.01878 DOI: http://dx.doi.org/10.3389/fimmu.2018.01878 | International search | [XY] WO2017205810 (ETUBICS CORP et al.) [X] 1-4, 17, 18, 26-28 * entire document *[Y] 19 | [Y] WO2017156349 (COLD GENESYS INC et al.) [Y] 19 * entire document * | [A] US2017266270 (FOY SUSAN et al.) [A] 1-4, 17-19, 26-28 * entire document * | [A] US2017281743 (HAR-NOY MICHAEL et al.) [A] 1-4, 17-19, 26-28 * entire document * | [A] US2017196956 (NISHIMURA YASUHARU et al.) [A] 1-4, 17-19, 26-28 * entire document * | [A] US2016339090 (HACOHEN NIR et al.) [A] 1-4, 17-19, 26-28 * entire document * | by applicant | WO2018005973 | WO2015069770 | WO2016172249 | WO2017143449 | US2012059670 | US2012066001 | US2016056550 | WO2017035392 | WO2011139345 | WO2013062505 | WO2014193982 | WO2014059036 | WO2014210611 | WO2015184439 | WO2016118527 | SCIENCE, vol. 331, 2011, pages 1565 - 70 | ONCOTARGET, vol. 5, no. 7, 2014, pages 1869 - 1884 | KABACAOGLU ET AL.: "Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options", FRONTIERS IN IMMUNOLOGY, vol. 9, 2018, XP055821506, DOI: 10.3389/fimmu.2018.01878 DOI: http://dx.doi.org/10.3389/fimmu.2018.01878 | J IMMUNOL METHODS, vol. 374, 2011, pages 1 - 4 | PLOS NEGL TROP DIS., vol. 9, no. 1, January 2015 (2015-01-01), pages 3321 | MOLECULAR THERAPY, vol. 23, pages 222 - 223 | PLOS ONE, vol. 7, no. 7, 2012, pages 42094 |